Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/60—Sugars; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
  • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
  • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
  • A61K36/82—Theaceae (Tea family), e.g. camellia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q7/00—Preparations for affecting hair growth

Definitions

• compositions for promoting hair growth or hair growth Disclosed herein are compositions for anti-inflammatory.
• hair loss The causes of hair loss are discussed, such as hyperthermia of male hormone action, excessive sebum secretion, poor blood circulation, hypoxia caused by peroxide, bacteria, genetic factors, aging, stress.
• hair loss population is gradually increasing due to social stress and westernized eating habits such as environmental pollution and instant food, frequent perm and dyeing.
• Hair cycles include anagen, which grows hair, catagen, which ends growth and hairball shrinks, talogen, which is the time when the nipple stops working and the hair stays in the scalp. It can be divided into a generator, which is a time to start or to dehair old hair by generating new hair.
• the anagen stage (2-7 years) is the period of hair growth, which is divided into the stages of hair production, from which hair exits the hair follicles and the formation of hard keratin in the hair follicles. Hair continues to grow self-development.
• Cataract Stage (two to three weeks) is the period when the growth phase ends and metabolism slows down while maintaining the shape of the hair. This stage does not produce keratin.
• the degenerative stage accounts for 1% of all hair. At this time, the hair follicle contracts and is divided into the dermal papilla, surrounded by the hair follicle, and upwards, and cell division is stationary.
• the Talogen Stage (3 months) is followed by atrophy of the nipples, the hair follicles clumping gradually, and the roots being pushed upwards. The period of hair loss is 3-4 months until the next growth stage begins.
• Androgenetic alopecia is caused by a male hormone called Testosterone, which is converted to the more powerful hormone Dihydrotestosterone (DHT) by an enzyme called 5alpha-reductase. Hormones act on the hair follicles, leading the hair follicles from the growth phase to the degenerative phase, leading to hair loss. Therefore, a method of inhibiting the production of DHT by 5-alpha-reductase is mainly used to treat androgenetic alopecia.
• DHT Dihydrotestosterone
• Gynecologic alopecia is mainly caused by a decrease in the amount of estrogen after menopause.
• Minoxidil and estrogen are mainly used as treatments for gynecomastia.
• Alopecia areata is caused by autoimmune diseases, mental stress, or genetic predisposition. This alopecia areata is fundamentally different from androgenetic alopecia, and the treatment is also different, using a method of treating corticosteroids, or applying minoxidil to the affected area or artificially causing irritation in the affected area.
• the mediators responsible for inflammation include Vaso-active amines, Vaso-active polypeptides, and other mediators.
• Vascularly active amines include histamine and three secreted from mast cells. Letonin and the like mainly serves to promote vasodilation and permeability.
• vascular active polypeptides include kinin, plasmin, and complement, which act as a vasoconstrictor, and other lymphokines such as interleukin-6 (IL-6).
• IL-6 interleukin-6
• Arachidonic acid produced by phospholipase activated by physical and chemical stimuli, again passes through two pathways, cyclooxygenase (COX) or lipooxygenase, to prostaglandin, an inflammatory mediator. Metabolized to leukotriene to mediate various inflammatory responses (Thomas. R., Rev. Physiol. Biochem. Pharmacol., 100, 1984, Pub. 10-2008-0020853).
• the prior art is Korean Patent No. 10-1274029.
• the present disclosure is asamsaponin B (Assamsaponin B), Theasaponin E1 (Theasaponin E1), Theasaponin E2 (Theasaponin E2), Asamsaponin H (Assamsaponin H), Asamsaponin D (Assamsaponin D) and (Theasaponin C1) It is an object to provide a composition for promoting hair growth or hair growth comprising at least one selected from the group consisting of.
• the present disclosure is directed to Asamsaponin B, Theasaponin E1, Theasaponin E2, Asamsaponin H, Asamsaponin D, and Assamsaponin D1.
• Theasaponin C1 It is an object to provide an anti-inflammatory composition comprising at least one selected from the group consisting of as an active ingredient.
• the techniques disclosed herein are asamsaponin B, thesaponin E1, thesaponin E2, the asasaponin E2, and the asamsaponin H, which are represented by the above formula. It provides a composition for promoting hair growth or hair growth comprising at least one selected from the group consisting of (Assamsaponin D) and thiasaponin C1 (Theasaponin C1) as an active ingredient.
• the techniques disclosed herein include Asamsaponin B, Theasaponin E1, Theasaponin E2, Assamsaponin H, and Asamsaponin D represented by the above formula. It provides an anti-inflammatory composition comprising at least one selected from the group consisting of (Assamsaponin D) and thiasaponin C1 (Theasaponin C1) as an active ingredient.
• the active ingredient may be isolated from Camellia Seed extract.
• the composition may be to propagate hair follicular papilla cells.
• the composition may be to inhibit PGE2, IL-6 or IL-8 production.
• the active ingredient may be included in 0.001 to 20% by weight based on the total weight of the composition.
• the composition may be a pharmaceutical composition.
• the composition may be a cosmetic composition.
• the composition may be a food composition.
• the techniques disclosed herein include Asamsaponin B, Theasaponin E1, Thesaponin E2, Asamsaponin H, Asamsaponin D, and Asamsaponin D.
• There is an effect of providing a composition for promoting hair growth or hair growth comprising at least one selected from the group consisting of thiasaponin C1 (Theasaponin C1) as an active ingredient.
• the techniques disclosed herein include: Assamsaponin B, Thesaponin E1, Theasaponin E2, Asamsaponin H, Asamsaponin D, and Asamsaponin D. It is effective to provide an anti-inflammatory composition comprising at least one selected from the group consisting of thiasaponin C1 (Theasaponin C1) as an active ingredient.
• the technology disclosed herein has the effect of providing a pharmaceutical composition, cosmetic composition, food composition for promoting hair growth or hair growth, anti-inflammatory, which has no side effects and excellent stability by including a natural plant as an active ingredient.
• the techniques disclosed herein are asamsaponin B, thesaponin E1, thesaponin E2, the asasaponin E2, and the asamsaponin H, which are represented by the above formula. It provides a composition for promoting hair growth or hair growth comprising at least one selected from the group consisting of (Assamsaponin D) and thiasaponin C1 (Theasaponin C1) as an active ingredient.
• the techniques disclosed herein are asamsaponin B, thesaponin E1, theasaponin E2, and asasaponin represented by the above formulas for use in promoting hair growth or hair growth.
• the techniques disclosed herein are asamsaponin B, thesaponin E1, thesaponin E2, the assamsaponin H, and assamsaponin Hair growth, comprising administering to the subject in need of hair growth or hair growth a composition for promoting hair growth or hair growth comprising at least one selected from the group consisting of D (Assamsaponin D) and thiasaponin C1, or as an active ingredient Or provide a method for promoting hair growth.
• the administration can be carried out according to the administration method and administration dose described herein.
• the techniques disclosed herein are asamsaponin B, thiasaponin E1, and thiasaponin E2 represented by the above formula for preparing a composition for promoting hair growth or hair growth. And at least one use selected from the group consisting of Asamsaponin H, Asamsaponin D, and Theasaponin C1.
• the technology disclosed herein is assamsaponin B (Assamsaponin B), Theasaponin E1 (Theasaponin E1), Theasaponin E2 (Theasaponin E2), Assamsaponin H (Assamsaponin H), Assam represented by the above formula It provides an anti-inflammatory composition comprising at least one selected from the group consisting of Saponin D (Assamsaponin D) and thiasaponin C1 (Theasaponin C1) as an active ingredient.
• the techniques disclosed herein are asamsaponin B, theasaponin E1, theasaponin E2, and assamsaponin H represented by the above formula for use in anti-inflammatory. H), Asamsaponin D and Assasaponin C1 (Theasaponin C1).
• the techniques disclosed herein are asamsaponin B, thesaponin E1, thesaponin E2, the assamsaponin H, and assamsaponin Provides an anti-inflammatory method comprising administering at least one selected from the group consisting of D (Assamsaponin D) and thiasaponin C1 (Theasaponin C1), or an anti-inflammatory composition comprising them as an active ingredient to a subject in need of inflammation relief do.
• the administration can be carried out according to the administration method and administration dose described herein.
• the technology disclosed herein for preparing an anti-inflammatory composition, Asamsaponin B, Thesaponin E1, Theasaponin E2, The Asaponin E2, Assam It provides at least one use selected from the group consisting of Saponin H, Assamsaponin D and Theasaponin C1.
• the active ingredient may be isolated from Camellia Seed extract.
• Saponin Assamsaponin B, Theasaponin E1, Theasaponin E2, Assamsaponin H, Assamsaponin D or Theasaponin C1 isolated from the camellia seed extract are obtained from the camellia seed by using water or an organic solvent to obtain an extract containing saponin; And isolating Assamsaponin B, Theasaponin E1, Theasaponin E2, Assamsaponin H, Assamsaponin D, Theasaponin C1 from the extract.
• an extract containing saponin from the camellia seeds may be appropriately applied, modified or applied by a person of ordinary skill in the art selecting appropriately from a method for preparing an extract used in the art.
• the organic solvent may be at least one organic solvent selected from the group consisting of ethanol, methanol, butanol, ether, ethyl acetate and chloroform or a mixture of water and 50% ethanol in one aspect.
• 1 to 4 1), Assamsaponin B, Theasaponin E1, Theasaponin E2, Assamsaponin H, Assamsaponin D, Theasaponin C1 can be obtained.
• the composition may be to propagate hair follicular papilla cells.
• the composition has the effect of activating keratinocytes by proliferating follicular dermal papilla cells and promoting the production of hair by enhancing the expression of hair growth factor VEGF.
• the composition has an effect of promoting the growth of hair and preventing or improving hair loss by shortening the period of transition from the resting phase to the growth phase of the hair growth cycle.
• the composition may be to inhibit PGE2, IL-6 or IL-8 production.
• the active ingredient may be included in 0.001 to 20% by weight based on the total weight of the composition. According to another embodiment, the active ingredient may be included as 0.01 to 15% by weight, 0.01 to 10% by weight, or 0.1 to 5% by weight based on the total weight of the composition.
• the active ingredient included in the composition disclosed herein may be included as 0.001% by weight, 0.01% by weight, 0.1% by weight, or 1.0% by weight or more based on the total weight of the composition, and in another aspect 20 wt% or less, 15 wt% or less, 10 wt% or less, or 5 wt% or less.
• the content of 0.001% by weight or more is excellent in hair regrowth, hair growth, anti-inflammatory effect of the composition, it is contained in 20% by weight or less, easy to manufacture safety or formulation, and exhibits excellent efficacy without side effects. Can be.
• the composition may be a pharmaceutical composition.
• the pharmaceutical composition may further contain, in addition to the active ingredients disclosed herein, pharmaceutical supplements such as preservatives, stabilizers, hydrating or emulsifying accelerators, salts and / or buffers for controlling osmotic pressure, and other therapeutically useful substances, It may be formulated in various oral or parenteral dosage forms according to conventional methods.
• pharmaceutical supplements such as preservatives, stabilizers, hydrating or emulsifying accelerators, salts and / or buffers for controlling osmotic pressure, and other therapeutically useful substances, It may be formulated in various oral or parenteral dosage forms according to conventional methods.
• the oral dosage forms include, for example, tablets, pills, hard and soft capsules, solutions, suspensions, emulsifiers, syrups, powders, powders, fine granules, granules, pellets, and the like, and these formulations include surfactants in addition to active ingredients. , Diluents (eg lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and glycine), glidants (eg silica, talc, stearic acid and its magnesium or calcium salts and polyethylene glycols). .
• Diluents eg lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and glycine
• glidants eg silica, talc, stearic acid and its magnesium or calcium salts and polyethylene glycols.
• Tablets may also contain binders such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and polyvinylpyrrolidine, optionally starch, agar, alginic acid or its sodium salt Pharmaceutical additives such as disintegrants, absorbents, colorants, flavors, and sweeteners.
• binders such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and polyvinylpyrrolidine, optionally starch, agar, alginic acid or its sodium salt
• Pharmaceutical additives such as disintegrants, absorbents, colorants, flavors, and sweeteners.
• the tablets can be prepared by conventional mixing, granulating or coating methods.
• parenteral dosage form may be a transdermal dosage form, for example, an injection, drop, ointment, lotion, gel, cream, spray, suspension, emulsion, suppository, patch, or the like. It may be, but is not limited thereto.
• compositions according to one embodiment of the invention may be administered topically to the scalp, for example.
• the daily dosage of the drug depends on a variety of factors, such as the progress of the subject to be administered, the onset, age, health status, complications, etc. On the basis of one side may be administered by dividing the composition 1 ⁇ g / kg to 200 mg / kg, in another aspect 50 ⁇ g / kg to 50 mg / kg 1 to 3 times a day, the dosage is any The method does not limit the scope of the present invention.
• the pharmaceutical composition may be an external preparation for skin, and the external preparation for skin may be included herein as a generic term that may include anything applied outside the skin.
• the composition may be a cosmetic composition.
• the cosmetic composition may further include functional additives and components included in the general cosmetic composition in addition to the active ingredient disclosed herein.
• the functional additive may include a component selected from the group consisting of water-soluble vitamins, oil-soluble vitamins, polymer peptides, polymer polysaccharides, sphingolipids and seaweed extract.
• oils and fats moisturizers, emollients, surfactants, organic and inorganic pigments, organic powders, ultraviolet absorbers, preservatives, fungicides, antioxidants, plant extracts, pH adjusters, alcohols, pigments, flavorings, blood circulation And accelerators, cooling agents, limiting agents, purified water, and the like.
• the cosmetic composition is not particularly limited in formulation, and may be appropriately selected as desired.
• skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisturizing lotion, nutrition lotion, massage cream, nutrition cream, moisturizing cream, hand cream, foundation, essence, nutrition essence, pack, soap, cleansing It may be prepared in any one or more formulations selected from the group consisting of foam, cleansing lotion, cleansing cream, body lotion and body cleanser, but is not limited thereto.
• the formulation of the present invention is a paste, cream or gel
• animal carriers vegetable fibers, waxes, paraffins, starches, tracantes, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicas, talc or zinc oxide, etc.
• carrier components can be used as carrier components.
• lactose When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used, and especially in the case of spray, additionally chlorofluorohydrocarbon, propane Propellant such as butane or dimethyl ether.
• a solvent, solvating or emulsifying agent is used as the carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 Fatty acid esters of, 3-butylglycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan.
• liquid carrier diluents such as water, ethanol or propylene glycol
• suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystalline Cellulose, aluminum metahydroxy, bentonite, agar or tracant and the like can be used.
• the carrier component is an aliphatic alcohol sulfate, an aliphatic alcohol ether sulfate, a sulfosuccinic acid monoester, an isethionate, an imidazolinium derivative, a methyltaurate, a sarcosinate, a fatty acid amide.
• Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, linolin derivatives or ethoxylated glycerol fatty acid esters and the like can be used.
• the composition may be a food composition.
• the food composition may be in a liquid or solid dosage form, for example, various foods, beverages, gums, teas, vitamin complexes, dietary supplements, and the like, and may be used in the form of powders, granules, tablets, capsules, or beverages. Can be.
• the food composition of each formulation may be appropriately selected and blended by those skilled in the art according to the formulation or purpose of use, according to the formulation or purpose of use. Can happen.
• liquid component that can be contained in addition to the active ingredient disclosed herein, and may include various flavors or natural carbohydrates as additional ingredients, such as ordinary drinks.
• natural carbohydrates include conventional sugars such as disaccharides such as monosaccharides, glucose and fructose, polysaccharides such as maltose and sucrose, dextrins and cyclodextrins, and sugar alcohols such as xylitol, sorbitol and erythritol. Etc.
• natural flavoring agents such as, tauumatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (for example, saccharin, aspartame, etc.) can be advantageously used.
• the proportion of natural carbohydrates may generally be about 1-20 g, in one aspect about 5-12 g, per 100 ml of the composition disclosed herein.
• the food composition may contain various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, flavoring agents such as coloring and neutralizing agents (such as cheese, chocolate), pectic acid and salts thereof, alginic acid and salts thereof.
• it may include a pulp for the production of natural fruit juices and vegetable drinks.
• the components can be used independently or in combination.
• the ratio of the additive may vary, but is generally selected from 0.001 to about 20 parts by weight per 100 parts by weight of the composition disclosed herein.
• Assamsaponin B Assamsaponin B
• Thiasaponin E1 Theasaponin E1
• thiasaponin E2 Theasaponin E2
• Assamsaponin H Assamsaponin H
• Assamsaponin Preparation of Assamsaponin D Theasaponin C1
• camellia seed extract 3L of hexane was added to 1 kg of camellia seed (Camellia Seed), and extracted by stirring and extraction at room temperature. Then, 4 L of 50% ethanol was added to 0.5 kg of degreased camellia seed, and refluxed three times, followed by immersion at 15 ° C. for 1 day. Thereafter, the residue and the filtrate were separated through filter cloth filtration and centrifugation, and the separated filtrate was concentrated under reduced pressure to prepare a camellia seed extract.
• B41p1 (1.6 mg), B41p2 (Assamsaponin B, 3.9 mg), B42p1 (Theasaponin E1, 12.8 mg), B42p2 (Theasaponin E2, 5.6 mg), B43p2 (Assamsaponin H, 2.2 mg), B43p3 (Camelliasaponin B1, 1.6 mg), B44p1 (Assamsaponin D, 3 mg), B44p2 (Theasaponin C1, 1.6 mg) in total 8 kinds of substances were obtained (Scheme) Reference).
• Test Example 1 Increased expression of hair growth factor VEGF in dermal papilla cells
• Assamsaponin B, Theasaponin E1, Theasaponin E2, Assamsaponin H, Assamsaponin D, Theasaponin C1 are growth factors necessary for blood vessel formation and express Vascular endothelial growth factor (VEGF), which is a growth factor required to move to the hair growth phase
• VEGF Vascular endothelial growth factor
• the in vitro system was applied to evaluate the efficacy of Assamsaponin B, Theasaponin E1, Theasaponin E2, Assamsaponin H, Assamsaponin D, Theasaponin C1 derived from Camellia saponin.
• DPC male dermal papilla cells
• P.11 4 ⁇ 10 5 cells were seeded in 12-well plates, containing 10% FBS (fetal bovine serum). Incubated overnight in Dulbecco's modified Eagle's medium (DMEM) medium. After incubation, Assamsaponin B, Theasaponin E1, Theasaponin E2, Assamsaponin H, Assamsaponin D, Theasaponin C1 derived from camellia saponin were treated with 20 ppm, respectively. Theasaponin was used as a comparative example, and DMSO was used as a negative control.
• DPC male dermal papilla cells
• VEGF ELISA Vascular endothelial growth factor Enzyme-Linked Immunosorbent Assay
• Assamsaponin B, Theasaponin E1, Theasaponin E2, Assamsaponin H, Assamsaponin D, Theasaponin C1 can be seen that there is a significant difference in effect compared to the comparative example and the control, specifically, in the hair papilla cells The expression of growth factor VEGF was increased by about three times or more. Therefore, it can be seen that Assamsaponin B, Theasaponin E1, Theasaponin E2, Assamsaponin H, Assamsaponin D, Theasaponin C1 have excellent hair growth promoting ability.
• the keratin proteins that make up hair are produced in hair root keratinocytes, which are differentiated from dermal papilla cells. Therefore, if Assamsaponin B, Theasaponin E1, Theasaponin E2, Assamsaponin H, Assamsaponin D, Theasaponin C1 promote the activity of dermal papilla cells, they can promote the activity of keratinocytes that are differentiated therefrom and further promote hair production.
• Assamsaponin B, Theasaponin E1, Theasaponin E2, Assamsaponin H, Assamsaponin D, Theasaponin C1 was evaluated as follows.
• a human dermal papilla cell obtained from Professor Kwon Oh-sang, Seoul National University
• the cell line was incubated for 24 hours in an incubator maintained at 5% CO 2 and 37 ° C with Dulbecco's modified Eagle's medium (DMEM; Gibco BRL, Gaithersburg, MD, USA) containing 10% bovine serum serum (FBS), Assamsaponin B, Theasaponin E1, Theasaponin E2, Assamsaponin H, Assamsaponin D, and Theasaponin C1 derived from camellia saponin were treated with 20 ppm, respectively.
• Theasaponin was used as a comparative example, and DMSO was used as a negative control.
• Assamsaponin B, Theasaponin E1, Theasaponin E2, Assamsaponin H, Assamsaponin D, Theasaponin C1 showed a 1.5 times higher growth rate of dermal papilla cells than the comparative and control groups. This means that Assamsaponin B, Theasaponin E1, Theasaponin E2, Assamsaponin H, Assamsaponin D, Theasaponin C1 can promote the growth of dermal papilla cells, and more effectively promote the activity and hair production of keratinocytes.
• Hair follicles were isolated from the back of the scalp scalp tissue of a 55 year old male with William's E medium (L-glutamine (2 mM), insulin (10 ⁇ g / ml), hydrocortisone (40 ng / ml), antibiotics (1%), and antifungal agents (1). %) Containing).
• the hair follicles grown on the third day after culture were screened and cut into 3 mm, and the selected hair follicle tissues were treated with no drug.
• Assamsaponin D 5 ppm of Theasaponin C1
• Theasaponin was treated as a comparative example. After 8 days of treatment, length measurement and photographing were performed. The results are shown in Table 3.
• Test Example 4 PGE2 , Inhibits IL-6 and IL-8 production
• Human fibroblasts were seeded in 6-well culture plates at a concentration of 1 ⁇ 10 5 cells and incubated in 37 ° C. and 5% CO 2 incubator for 24 hours. After treatment with 500 ⁇ M of H 2 O 2 in the wells for 24 hours, they were treated with Assamsaponin B, Theasaponin E1, Theasaponin E2, Assamsaponin H, Assamsaponin D, Theasaponin C1, and Theasaponin as comparative examples, respectively. The reaction was carried out for 48 hours. After completion of the reaction, the culture was collected and subjected to ELISA analysis. In this case, alpha-bisabolol ( ⁇ -bisabolol), which is a material frequently used as an anti-inflammatory and irritant, was used as a control.
• ⁇ -bisabolol alpha-bisabolol
• PGE2 used Asay Design's kit, IL-6 and IL-8 used Endogen's kit, and the experiment was conducted according to the method specified in each company's manual.
• the inhibitory effect was calculated according to Equation 1 below, and the measurement results are shown in Table 4 below.
• Inhibitory effect ⁇ 1- (test sample-control) / (H 2 O 2 -control) ⁇ ⁇ 100
• the ointment was prepared in a conventional manner according to the composition described in Table 7.
• Hair tonic was prepared by a conventional method according to the composition shown in Table 8.
• the lotion was prepared in a conventional manner according to the composition described in Table 11 below.
• the mixture was mixed, and 400 mg per capsule was filled according to a conventional method to prepare a soft capsule.
• 50 mg of one or more compounds selected from the group consisting of Assamsaponin B, Theasaponin E1, Theasaponin E2, Assamsaponin H, Assamsaponin D, Theasaponin C1, 250 mg of anhydrous glucose, and 550 mg of starch are mixed and molded into granules using a fluid bed granulator and It was filled in to prepare a granule.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Natural Medicines & Medicinal Plants (AREA)
• Epidemiology (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Dermatology (AREA)
• Mycology (AREA)
• Engineering & Computer Science (AREA)
• Botany (AREA)
• Microbiology (AREA)
• Medical Informatics (AREA)
• Biotechnology (AREA)
• Birds (AREA)
• Alternative & Traditional Medicine (AREA)
• Molecular Biology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Coloring Foods And Improving Nutritive Qualities (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Cosmetics (AREA)
• Food Science & Technology (AREA)
• Polymers & Plastics (AREA)
• Nutrition Science (AREA)
• Medicines Containing Plant Substances (AREA)

Priority Applications (6)

Applications Claiming Priority (2)

Publications (2)

Family

ID=57006157

Family Applications (1)

Country Status (8)

Families Citing this family (6)

Family Cites Families (9)

• 2015
  • 2015-03-31 KR KR1020150045134A patent/KR101957849B1/ko active IP Right Grant
• 2016
  • 2016-03-24 JP JP2017550108A patent/JP6697479B2/ja active Active
  • 2016-03-24 WO PCT/KR2016/002976 patent/WO2016159567A2/ko active Application Filing
  • 2016-03-24 MY MYPI2017703528A patent/MY182581A/en unknown
  • 2016-03-24 CN CN201680025764.3A patent/CN107530258B/zh active Active
  • 2016-03-24 SG SG11201707761WA patent/SG11201707761WA/en unknown
• 2017
  • 2017-09-19 PH PH12017501722A patent/PH12017501722A1/en unknown
• 2018
  • 2018-03-02 HK HK18103044.0A patent/HK1243356A1/zh unknown

Also Published As

Similar Documents

Legal Events